For more than 50 years, Laboratorios Rubio, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutical value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets. Laboratorios Rubio's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only to a small number of patients and that require the development of specific pharmaceutical products to treat them.

Within the niche market strategy, Laboratorios Rubió has been pioneer and innovative company among the Spanish pharmaceutical companies focus on, but not limited, to therapeutical areas such as: CNS, Anti-rheumatic, Nephrology, Urology, CV, GI, Psychiatry, etc. It is worth highlighting the success of RUBIFEN® & RUBIFEN® RETARD (Methylphenidate), RESINCALCIO® (Calcium Polystyrene Sulphonate), RESINSODIO® (Sodium Polystyrene Sulphonate), RESINCOLESTIRAMINA® (Cholestyramine), RUBI-DIET® NEFRO & RUBI-DIET® NEFRO PLUS (nutrition in CKD) and MELATONIN.

For more information, please visit us on www.laboratoriosrubio.com

Related Categories

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity

Manufacturer/Innovator